Assessing feasibility and risk to translate, de-identify and summarize medical letters using deep learning

Background Precision medicine requires accurate phenotyping and data sharing, particularly for rare diseases. However, sharing medical letters across language barriers is challenging, as inconsistent and incomplete Human Phenotype Ontology (HPO) terms provided by physicians can lead to a loss of clinical information.

Methods To assess the feasibility and the risk of using deep learning methods to translate, de-identify and summarize medical letters, we developed an open-source deep learning multi-language software in line with health data privacy. We conducted a non-inferiority clinical trial using deep learning methods versus a physician to de-identify protected health information (PHI) targeting a minimum sensitivity of 90% and specificity of 75%, and summarize non-English medical letters in HPO format, aiming a sensitivity of 75% and specificity of 90%.

Results From March to April 2023, we evaluated 50 non-English medical letters from 8 physicians coming from 12 different indications of which neurodevelopmental disorders, congenital disorders, fetal pathology and oncology. Letter contains in median 15 PHI and 7 HPO terms. Deep learning method achieved a sensitivity of 99% and a specificity of 87% in de-identification, and a specificity of 92% in summarizing medical letters, reporting a median number of 6,6 HPO terms per letter, which is equivalent to the number of HPO terms provided usually by physicians in databases (6,8 in PhenoDB).

Conclusions De-identification and summarization of non-English medical letters using deep learning methods, compared with the current manual physician’s method reports non-inferior performance, providing insights on AI usage to facilitate precision medicine.